These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 18588607)

  • 1. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder.
    Nakaaki S; Murata Y; Furukawa TA
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):370. PubMed ID: 18588607
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
    Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
    [No Abstract]   [Full Text] [Related]  

  • 3. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
    König F; von Hippel C; Petersdorff T; Neuhöffer-Weiss M; Wolfersdorf M; Kaschka WP
    Neuropsychobiology; 2001; 43(3):170-4. PubMed ID: 11287796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine treatment of body dysmorphic disorder.
    Hollander E; Cohen L; Simeon D; Rosen J; DeCaria C; Stein DJ
    J Clin Psychopharmacol; 1994 Feb; 14(1):75-7. PubMed ID: 8151008
    [No Abstract]   [Full Text] [Related]  

  • 6. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
    Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
    Zink M; Knopf U; Kuwilsky A
    Aust N Z J Psychiatry; 2007 Mar; 41(3):293-4. PubMed ID: 17464712
    [No Abstract]   [Full Text] [Related]  

  • 9. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine.
    O'Sullivan RL; Phillips KA; Keuthen NJ; Wilhelm S
    Psychosomatics; 1999; 40(1):79-81. PubMed ID: 9989126
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E44-5. PubMed ID: 24763791
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine augmentation of fluoxetine in trichotillomania: two cases.
    Srivastava RK; Sharma S; Tiwari N; Saluja B
    Aust N Z J Psychiatry; 2005; 39(1-2):112-3. PubMed ID: 15660718
    [No Abstract]   [Full Text] [Related]  

  • 12. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
    Abraham JT; Brown R; Meltzer HY
    Biol Psychiatry; 1997 Jul; 42(2):144-6. PubMed ID: 9209732
    [No Abstract]   [Full Text] [Related]  

  • 13. Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder.
    Heiden A; de Zwaan M; Frey R; Presslich O; Kasper S
    J Psychiatry Neurosci; 1998 May; 23(3):179-80. PubMed ID: 9595892
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
    Ghaemi SN; Kirkwood CK
    J Clin Psychopharmacol; 1998 Aug; 18(4):342-3. PubMed ID: 9690702
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder.
    Bejerot S; Bodlund O
    Acta Psychiatr Scand; 1998 Nov; 98(5):423-4. PubMed ID: 9845182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of obsessive-compulsive disorder related to AIDS: psychopharmacologic treatment.
    Schechter JB; Myers MF; Solyom L
    Can J Psychiatry; 1991 Mar; 36(2):118-20. PubMed ID: 2044029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comments on article by Albers et al: "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy".
    Chiu CC; Lu ML
    J Clin Psychopharmacol; 2005 Dec; 25(6):626-7; author reply 627-8. PubMed ID: 16282861
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic Cotard's syndrome: recovery from 2 years' bed-ridden status.
    Chou PH; Lin BT; Lan TH; Chan CH
    Psychiatry Clin Neurosci; 2011 Apr; 65(3):301. PubMed ID: 21507141
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].
    Schmitt A; Braus DF
    Dtsch Med Wochenschr; 2000 Dec; 125(50):1526-9. PubMed ID: 11190762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine-induced psychotic mania.
    Christensen RC
    Am J Psychiatry; 1995 Sep; 152(9):1399-400. PubMed ID: 7653703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.